Therapeutic use of a triple-active, long-acting conjugate with activity at all glucagon, GLP-1 and GIP receptors in pulmonary diseases

JP7766602B2Active Publication Date: 2025-11-10HANMI PHARM CO LTD
7 Cites 0 Cited by

Patent Information

Application Number
JP2022542765
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-10-16
Filing Date
2020-11-20
Publication Date
2025-11-10
Estimated Expiration
2040-11-20
Patent Text Reader

Abstract

The present invention relates to the preventive or therapeutic use of a triple-active compound and / or a conjugate thereof that has activity against all of the glucagon, GLP-1 and GIP receptors for pulmonary diseases.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • A triple-active, long-acting conjugate with activity at all glucagon, GLP-1, and GIP receptors

    JP2019504055A

  • Triple active compound with activity at glucagon, GLP-1 and GIP receptors

    JP2019504057A

  • Pharmaceutical composition comprising a triple-active compound active at all of glucagon, GLP-1 and GIP receptors, and insulin

    JP2022515229A

  • Triple glucagon / GLP-1 / GIP receptor agonist

    US10370426B2

  • Long-acting conjugate of triple glucagon / GLP-1 / GIP receptor agonist

    US10400020B2